Ascendis Pharma (ASND)
(Delayed Data from NSDQ)
$139.65 USD
-0.01 (-0.01%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $139.50 -0.15 (-0.11%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Ascendis Pharma A/S [ASND/]
Reports for Purchase
Showing records 61 - 80 ( 303 total )
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Revisiting the CMC Issue Holding Up U.S. Approval for TCPTH; Adding to BIL
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Single Deficiency Puts TC-PTH Back on Path to Approval
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
TC-PTH NDA Clarity in the Coming Days; SKYTROFA Growth Impresses; 1Q23
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Expert Reviews Support Likelihood of TC-PTH FDA Approval After Minor Delay
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Minor Setback on TC-PTH NDA Creates Attractive Buying Opportunity
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
As The Dust Settles -- Sifting Through The Biotech Carnage, We See Opportunity
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Infigratinib/ACH Data: Assessing the Impact to BMRN''s VOXZOGO & ASND''s TC-CNP
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
HP Expert Survey Supports Rapid & Robust Uptake for TCPTH; PT to $195
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A